Clinical trials: Vehicle
Actinic Keratosis
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than…
- Trial name
- NCT02952898
- Testing
- GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
- Where
- 16 sites in United States
- Volunteers
- 665 people
- Sponsor
- Balmoral Medical company
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the…
- Trial name
- NCT02140060
- Testing
- Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension
- Volunteers
- 327 people
- Sponsor
- Alcon Research
Presbyopia
A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.
Study of safety and efficacy of UNR844 in subjects with presbyopia.
- Trial name
- READER (NCT04806503)
- Testing
- UNR844
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 234 people
- Sponsor
- Novartis Pharmaceuticals
Alopecia, Baldness
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss.
- Trial name
- NCT01325350
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- 2 sites in United States, Germany
- Volunteers
- 306 people
- Sponsor
- Allergan
Healthy
Bioavailability of Amoxicillin Dissolved in Human Milk
The investigators propose to study amoxicillin absorption in a 2-stage program that will progressively produce, for the first time, information leading to pediatric pharmacology recommendations for the administration to children…
- Trial name
- NCT01435824
- Testing
- Human milk-dissolved amoxicillin, Water-dissolved amoxicillin
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Actinic Keratosis
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.
- Trial name
- NCT02616601
- Testing
- Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
- Where
- 17 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Primary Open Angle Glaucoma, Ocular Hypertension
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
This study will evaluate the safety and efficacy of PF 03187207.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT00441883
- Testing
- PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
- Where
- 19 sites in United States
- Volunteers
- 176 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Hypertension, Open Angle Glaucoma
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
- Trial name
- NCT02874846
- Testing
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aerie Pharmaceuticals
Cutaneous Neurofibroma, Neurofibromatosis 1
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
This is a randomized, double-blind, vehicle-controlled, parallel group dose response study evaluating the safety and effectiveness of 2 concentrations of NFX-179 gel in participants with cNF.
- Trial name
- NCT05005845
- Testing
- NFX-179 gel, Vehicle gel
- Where
- 23 sites in United States
- Volunteers
- 199 people
- Sponsor
- NFlection Therapeutics, Inc.
Actinic Keratosis
Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis
This Phase 2 clinical trial is a multi-center, randomized, double-blind, placebo-controlled, multiple-dose, parallel-cohort study to assess the efficacy, safety and tolerability of VDA-1102 in the treatment of actinic keratosis…
- Trial name
- NCT02844777
- Testing
- 5% VDA-1102, 10% VDA-1102
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Vidac Pharma
Inflammation Corneal, Pain, Postoperative
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract…
- Trial name
- SKYGGN (NCT04130802)
- Testing
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- Where
- 4 sites in United States
- Volunteers
- 153 people
- Sponsor
- Oculis
Conjunctivitis, Allergic
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a…
- Trial name
- NCT01289431
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Bausch & Lomb Incorporated
Chronic Hand Eczema
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema
- Trial name
- NCT04378569
- Testing
- ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
- Where
- 37 sites in United States, Australia and 1 more
- Volunteers
- 230 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Presbyopia
A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
This clinical study will evaluate pilocarpine hydrogen chloride (HCl) ophthalmic solution (AGN-190584) in an expanded participant population to establish efficacy, safety, and tolerability versus the vehicle-control when…
- Trial name
- GEMINI 2 (NCT03857542)
- Testing
- Pilocarpine HCl Ophthalmic Solution, Vehicle
- Where
- 35 sites in United States
- Volunteers
- 427 people
- Sponsor
- Allergan
Dry Eye Disease
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
This is a Phase 2b, multicenter, vehicle-controlled, double-masked, randomized study. All subjects enrolled will have dry eye disease.
- Trial name
- COMET-1 (NCT04498182)
- Testing
- AR-15512 Ophthalmic Solution, AR-15512 Ophthalmic Solution Vehicle
- Where
- 15 sites in United States
- Volunteers
- 369 people
- Sponsor
- Aerie Pharmaceuticals
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
- Trial name
- NCT01017120
- Testing
- Tazarotene Foam, Vehicle Foam
- Where
- 18 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Stiefel, a GSK Company
Allergic Conjunctivitis
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01685242
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Aciex Therapeutics, Inc.
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608450
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 54 sites in United States, Georgia and 1 more
- Volunteers
- 708 people
- Sponsor
- Cassiopea SpA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.